A Cost Analysis of the HIV-STI Linkages Implementation
Analysis of the costs of staff time to link HIV and STI surveillance data across four jurisdictions over a two-year period.
Resource (Conference Presentation) updated 09/14/2023
Analysis of the costs of staff time to link HIV and STI surveillance data across four jurisdictions over a two-year period.
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
BLOC partners share how the BLOC program and curriculum were developed, implemented, and evaluated, including adaptations for key populations.
Resource (Conference Presentation) updated 09/14/2023
This 12-week pilot program focused on addressing the needs of long-term survivors.
Resource (Conference Presentation) updated 09/14/2023
Resource updated 10/24/2023
Resource updated 05/11/2023
Resource updated 12/19/2023
Resource updated 10/18/2023
Resource updated 05/10/2023
Resource from the RWHAP Best Practices Compilation updated on 05/14/2024
Resource updated 06/27/2024
Resource from the RWHAP Best Practices Compilation updated on 11/13/2023
RWHAP Technical Assistance Provider updated on 07/09/2024
Resource from the RWHAP Best Practices Compilation updated on 11/14/2023
RWHAP Technical Assistance Provider updated on 02/27/2024
Resource from the RWHAP Best Practices Compilation updated on 06/21/2024
By cross matching registries of HIV and other sexually transmitted infections, this study found 27.1% of male syphilis cases were coinfected with HIV and 31.8% of those coinfected were not virally suppressed. This suggests ongoing sexual risk behaviors and the potential for HIV transmission among male syphilis cases.
Resource (Conference Presentation) updated 09/14/2023
In a single-center restrospective cohort study, patients with extensive treatment experience and history of virologic failure and multi-drug resistance underwent simplification of ARV salvage regimens with a median pill burden reduction of six pills per day. This strategy led to high rates of virologic suppression.
Resource (Conference Presentation) updated 09/14/2023
The first long-acting injectable antiretroviral therapy (LAI ART) formulation was FDA-approved January 2021. Drawing on the Consolidated Framework on Implementation Research, this mixed methods study assessed knowledge, attitudes, practices, and perceived barriers and facilitators related to implementation of LAI ART in NYC among HIV clinic staff and people with HIV.
Resource (Conference Presentation) updated 09/14/2023